Jefferies Group’s Acceleron Pharma XLRN Stock Holding History

Jefferies Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$1.25M	–	2184
2021 Q2	$1.25M	Hold	10,000	–	–	0.01%	907
2021 Q1	$1.36M	Buy	+10,000	New	+$1.29M	0.01%	802
2015 Q2	–	Sell	-49,700	Closed	-$1.89M	–	3571
2015 Q1	$1.89M	Hold	49,700	–	–	0.01%	776
2014 Q4	$1.94M	Buy	+49,700	New	+$1.73M	0.01%	723

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Jefferies Group's XLRN Position: Q3 2021 in Review

Jefferies Group sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 2,519 shares — an estimated $316K sold.

Jefferies Group first reported a position in XLRN in Q1 2015 and held it in 8 quarters. The position peaked at $343K in Q1 2015. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Jefferies Group reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Jefferies Group sold 2,519 Acceleron Pharma shares in Q3 2021, an estimated $316K.
Jefferies Group first reported a position in Acceleron Pharma in Q1 2015 and held it in 8 quarters.
Jefferies Group's Acceleron Pharma position peaked at $343K in Q1 2015.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.